Beam Therapeutics (BEAM) Stock Forecast & Price Target $26.81 -1.12 (-4.01%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$26.90 +0.10 (+0.35%) As of 06:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Beam Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 14 Analyst RatingsSell1Hold3Buy10 Based on 14 Wall Street analysts who have issued ratings for Beam Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a sell rating, 3 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for BEAM. Consensus Price Target $46.8374.69% Upside According to the 14 analysts' twelve-month price targets for Beam Therapeutics, the average price target is $46.83. The highest price target for BEAM is $80.00, while the lowest price target for BEAM is $21.00. The average price target represents a forecasted upside of 74.69% from the current price of $26.81. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for BEAM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Beam Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BEAM Analyst Ratings Over TimeTypeCurrent Forecast5/19/25 to 5/19/261 Month Ago4/19/25 to 4/19/263 Months Ago2/18/25 to 2/18/261 Year Ago5/19/24 to 5/19/25Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)Buy9 Buy rating(s)11 Buy rating(s)12 Buy rating(s)11 Buy rating(s)Hold3 Hold rating(s)3 Hold rating(s)3 Hold rating(s)2 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price Target$46.83$49.36$43.80$48.75Forecasted Upside74.69% Upside57.24% Upside58.93% Upside176.05% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy BEAM Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History BEAM Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Beam Therapeutics Stock vs. The CompetitionTypeBeam TherapeuticsMedical CompaniesBroader MarketConsensus Rating Score 2.71 2.30 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside74.69% Upside1,693.87% Upside17.04% UpsideNews Sentiment RatingNeutral NewsSee Recent BEAM NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/13/2026 Tudor Pickering5 of 5 starsWilliam PickeringNot RatedSet Target$39.00+23.50%5/13/2026 Sanford C. Bernstein4 of 5 starsWilliam PickeringNot RatedLower TargetOutperform$40.00 ➝ $39.00+23.50%4/20/2026 Weiss RatingsNot Rated Reiterated RatingSell (D-)3/26/2026 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSamantha SemenkowSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$64.00 ➝ $68.00+186.41%2/25/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLuca IssiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetSector Perform$22.00 ➝ $26.00-19.74%2/25/2026 WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid NierengartenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$57.00 ➝ $65.00+101.30%2/20/2026 Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingWhitney IjemSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$74.00+165.42%1/7/2026 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael YeeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy ➝ Neutral$28.00-1.20%11/24/2025 EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingCory KasimovSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOutperform$35.00+57.59%11/17/2025 BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingSpeculative Buy Get the Latest News and Ratings for BEAM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/10/2025 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingPatrick R.Subscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$80.00+187.05%10/9/2025 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEric JosephSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$48.00 ➝ $46.00+80.17%10/9/2025 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Initiated CoverageHold ➝ Buy$41.00+43.29%8/6/2025 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGena WangSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetEqual Weight$25.00 ➝ $21.00+17.55%7/21/2025 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy5/7/2025 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDebjit ChattopadhyaySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$78.00 ➝ $55.00+250.32%5/7/2025 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYanan ZhuSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$75.00 ➝ $70.00+343.63%3/28/2025 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAlec StranahanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeNeutral ➝ Buy$42.00 ➝ $42.00+89.27%3/10/2025 JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSoumit RoySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeHold ➝ Buy$34.00+26.87%3/10/2025 ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGreg HarrisonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeSector Perform ➝ Sector Outperform$40.00+62.10%11/6/2024 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeMarket Perform ➝ Outperform$27.00 ➝ $39.00+62.98%9/11/2024 Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$66.00 ➝ $69.00+191.75%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:29 AM ET. BEAM Forecast - Frequently Asked Questions What is Beam Therapeutics' forecast for 2026? According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Beam Therapeutics is $46.83, with a high forecast of $80.00 and a low forecast of $21.00. Should I buy or sell Beam Therapeutics stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There is currently 1 sell rating, 3 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BEAM shares. Does Beam Therapeutics's stock price have much upside? According to analysts, Beam Therapeutics's stock has a predicted upside of 74.69% based on their 12-month stock forecasts. What analysts cover Beam Therapeutics? Beam Therapeutics has been rated by research analysts at Canaccord Genuity Group, Citigroup, Royal Bank Of Canada, Sanford C. Bernstein, Tudor Pickering, Wedbush, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Beam Therapeutics more than its competitors? Analysts like Beam Therapeutics more than other "medical" companies. The consensus rating for Beam Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how BEAM compares to other companies. Stock Forecasts and Research Tools Related Companies CRSP Stock Forecast DNLI Stock Forecast EDIT Stock Forecast NTLA Stock Forecast PRME Stock Forecast TWST Stock Forecast BBIO Stock Forecast ELAN Stock Forecast AXSM Stock Forecast RDY Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Beam Therapeutics RecommendationsSanford C. BernsteinTudor PickeringWeiss RatingsCitigroupWall Street ZenWedbushRoyal Bank Of CanadaCanaccord Genuity GroupUBS GroupEvercoreBenchmarkHC WainwrightJPMorgan Chase & Co.Jefferies Financial GroupBarclays This page (NASDAQ:BEAM) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
